![Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial - The Lancet Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2119419564/2093596899/gr1.gif)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial - The Lancet
![Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology](https://www.thelancet.com/cms/asset/28f62488-d818-4e72-ba24-1636b3b8d894/gr1.jpg)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
![Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study - Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study -](https://www.thelancet.com/cms/attachment/2005796916/2025323594/gr1.gif)
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study -
![Frontiers | Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management Frontiers | Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management](https://www.frontiersin.org/files/Articles/713700/fendo-12-713700-HTML/image_m/fendo-12-713700-g001.jpg)
Frontiers | Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
![Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial - The Lancet Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial - The Lancet](https://www.thelancet.com/cms/asset/95686e50-6ec8-4621-88c8-956e421655da/gr1.jpg)
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial - The Lancet
![Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial - The Lancet Oncology Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2119431747/2093731489/gr1.gif)